Pan Mersey
Area Prescribing Committee
 
back
8 Malignant disease and immunosuppression

Review date: January 2022

Non-formulary drugs: Any drug or formulation not listed in the formulary is deemed to be non-formulary.

Off-label use: Drugs are included in the formulary for their licensed indications – where inclusion of off-label use is considered to be included in the formulary this is specifically stated in the formulary entry for the drug N.B. also see Paediatrics note below.

Paediatrics: Drugs are included in the formulary for paediatric use for their BNF for Children recommended indications (indicated by symbol View childrens BNF) which may be off-label, unless otherwise stated. All drugs are deemed to have the same RAG status as they have for adults unless stated otherwise.

NHS England Specialised Commissioning
Drugs carrying the NHS England logo are commissioned by them. Links to key documents, national programmes of care, and clinical reference groups are found below.

NHSE NHS England Specialised Commissioning: Key documents

NHSE NHS England Specialised Commissioning: National programmes of care and clinical reference groups

Medications which are indicated for medically assisted reproduction, including ovulation induction (e.g. clomifene, letrozole and tamoxifen) and assisted reproduction, such as In Vitro Fertilisation or Ex Vitro Fertilisation (e.g. gonadotrophins) are restricted to use by specialist secondary care physicians, and are categorised as RED drugs for these purposes.

08-02-04 Lenalidomide, pomalidomide, and thalidomide

Lenalidomide
Formulary

Capsules 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg, 25mg


NHS NHSE commissioned drug - see Specialised Commissioning: Key documents

Link  NICE TA171 (2009): Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Link  NICE TA322 (2014): Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Link  NICE TA586 (2019): Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Link  NICE TA587 (2019): Lenalidomide plus dexamethasone for previously untreated multiple myeloma
 

Red View adult BNF  View SPC online
Pomalidomide
Formulary

Capsules 1mg, 2mg, 3mg, 4mg

NHS NHSE commissioned drug - see Specialised Commissioning: Key documents

Link  NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (replaces TA338)
 

Red View adult BNF  View SPC online
Thalidomide
Formulary

Capsules 50mg


NHS NHSE commissioned drug - see Specialised Commissioning: Key documents

Link  Bortezomib and thalidomide for the first line treatment of multiple myeloma (TA228), National Institute for Health and Care Excellence Technology Appraisal
 

Red View adult BNF  View SPC online